2021 ICD-10-CM Code C34.81

Malignant neoplasm of overlapping sites of right bronchus and lung

Version 2021

Valid for Submission

ICD-10:C34.81
Short Description:Malignant neoplasm of ovrlp sites of right bronchus and lung
Long Description:Malignant neoplasm of overlapping sites of right bronchus and lung

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of respiratory and intrathoracic organs (C30-C39)
      • Malignant neoplasm of bronchus and lung (C34)

C34.81 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of overlapping sites of right bronchus and lung. The code C34.81 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.

The code C34.81 is linked to some Quality Measures as part of Medicare's Quality Payment Program (QPP). When this code is used as part of a patient's medical record the following Quality Measures might apply: Lung Cancer Reporting (biopsy/cytology Specimens) , Lung Cancer Reporting (resection Specimens).

Convert C34.81 to ICD-9 Code

The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C34.81 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.

Quality Payment Program Measures

When code C34.81 is part of the patient's diagnoses the following Quality Measures apply and affect reimbursement. The objective of Medicare's Quality Measures is to improve patient care by making it more: effective, safe, efficient, patient-centered and equitable.

Quality Measure Description Quality Domain Measure Type High Priority Submission Methods
Lung Cancer Reporting (Biopsy/Cytology Specimens)Pathology reports based on biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type or classified as non-small cell lung cancer not otherwise specified (NSCLC-NOS) with an explanation included in the pathology report.Communication and Care CoordinationProcessYESClaims, Registry
Lung Cancer Reporting (Resection Specimens)Pathology reports based on resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type.Communication and Care CoordinationProcessYESClaims, Registry

Information for Patients


Lung Cancer

Also called: Bronchogenic carcinoma

Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk.

Common symptoms of lung cancer include

Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute


[Learn More in MedlinePlus]

Code History

  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)